News
AbbVie and REGENXBIO Announce Eye Care Collaboration
News
AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration

November 11, 2021
AbbVie photo

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) recently announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Currency: USD
USD - US Dollar
EUR - Euro
GBP - British Pound
CAD - Canada Dollars
AUD - Australia Dollars
JPY - Japan Yen
SEK - Sweden Kronor
NOK - Norway Kroner
IDR - Indonesia Rupiahs
BRL - Brazil Reais
RUB - Russia Rubles
THB - Thailand Baht
AED - Arab Emir. Dirham
Need Help?
Chat live with us
Request Quote
Want to call?

86-13799759387

WhatsApp
Track Order
Want to check the status of your order? You can put in your order number and click track order to find the tracking information or login your account to check the detail information.
order number
  • order number
  • tracking number